Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GH ResearchFRA:1KA -7.41%40 10-Year ROIIC % is -35.21 as of Dec. 2025. GuruFocus rates FRA:1KA with a GF Score™ of 40/100. The stock has 2 warning signs investors should review. Among 1,107 Biotechnology companies, GH Research ranks worse than 55.01% on this metric.
10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
GH Research does not have enough data to calculate 10-Year ROIIC %.
GH Research (FRA:1KA) 10-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
GH Research 10-Year ROIIC % Related Terms
GH Research 10-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for GH Research's 10-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1KA vs ATAI, RAPP, NUVB: 10-Year ROIIC % Comparison
For the Biotechnology subindustry, GH Research's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GH Research 10-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GH Research's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where GH Research's 10-Year ROIIC % falls into.
GH Research's 10-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
10-Year ROIIC %
=
10-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
10-Year Incremental Invested Capital**
=
( -51.817 (Dec. 2025) - (Dec. 2015) )
/
( 2.584 (Dec. 2025) - (Dec. 2015) )
=
/
=
N/A%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
GH Research (FRA:1KA) has a 10-Year ROIIC % of -35.21 as of Dec. 2025. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on GH Research and its competitors. According to the industry distribution chart, GH Research ranks #609 out of 1107 companies in the Biotechnology industry, placing it in the top 55%.
Is GH Research's 10-Year ROIIC % too high?
GH Research's current 10-Year ROIIC % is -35.21. Based on the distribution chart, GH Research ranks #609 out of 1107 companies in the Biotechnology industry, which is below the industry midpoint. Overall, GH Research has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does GH Research's 10-Year ROIIC % compare to ATAI and RAPP?
According to the Biotechnology industry distribution chart, GH Research ranks #609 out of 1107 companies for 10-Year ROIIC %. This places GH Research in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year ROIIC % for a Biotechnology company?
A good 10-Year ROIIC % depends on the Biotechnology industry context. However, 10-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year ROIIC % mean?
A high 10-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on GH Research and its competitors. GH Research's current 10-Year ROIIC % is -35.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GH Research stock overvalued right now?
GH Research (FRA:1KA) has a current 10-Year ROIIC % of -35.21. The current 10-Year ROIIC % is -35.21. GH Research's overall GF Score™ is 40/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year ROIIC % calculated?
10-Year ROIIC % is calculated from a company's financial statements. For GH Research (FRA:1KA), the current 10-Year ROIIC % is -35.21 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
40GF Score
Get the complete analysis for FRA:1KA
10-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1KA has been successfully added to your 
